<DOC>
	<DOCNO>NCT00486850</DOCNO>
	<brief_summary>Title Study : A Prospective , Randomized , Multicenter Trial Comparing Synchronized Intermittent Mandatory Ventilation ( SIMV ) v . Early Extubation Nasal Intermittent Positive Pressure Ventilation ( NIPPV ) Surfactant Treatment Preterm Infants Respiratory Distress Treatment Period ( Planned ) : 7 day Objectives : To compare impact early extubation [ within 120 minute birth Nasal Intermittent Positive Pressure Ventilation ( NIPPV group ) vs. Synchronized Intermittent Mandatory Ventilation ( SIMV group ) incidence mechanical ventilation via endotracheal tube 7 day age 26 29 + 6 week gestation premature infant respiratory distress treat intratracheal Curosurf ( poractant alpha ) within 60 minute birth . Secondary objective include evaluation overall clinical outcome 7 day , 28 day , 36 week postmenstrual age ( PMA ) and/or discharge , complication , safety , adverse event . Number Subjects : 110</brief_summary>
	<brief_title>Synchronized Intermittent Mandatory Ventilation ( SIMV ) Versus Nasal Intermittent Positive Pressure Ventilation ( NIPPV ) In Preterm Infants With Respiratory Distress</brief_title>
	<detailed_description>Respiratory management : SIMV group : Infants randomize SIMV maintain SIMV per standard unit protocol . Infant progressively wean extubated NCPAP infant meet minimum criterion extubation . Caffeine administer around time extubation . NIPPV group : Extubated NIPPV within 120 minute birth fraction inspire oxygen ( FiO2 ) less 0.60 first dose surfactant . Caffeine administer around time extubation . Infant reintubated clinical parameter necessitate mechanical ventilation . NIPPV may discontinue patient wean positive end expiratory pressure 5 cmsH20 back rate &lt; 10 bpm FiO2 &lt; 0.30 24 hour nasal continuous positive airway pressure ( NCPAP ) . Surfactant administration : Prior randomization enrollment , infant receive initial dose poractant alfa 200mg/kg . Subsequent dose 100mg/kg give 12 hour initial dose base upon clinical criterion . Up 2 additional dos give within 48 hour age infant remain intubated . Criteria Evaluation Primary Endpoint : The need mechanical ventilation via endotracheal tube 7 day age . Secondary Endpoints : Additional dos surfactant , duration ( day ) mechanical ventilation , duration ( day ) supplemental oxygen , day NIPPV , day CPAP , use postnatal steroid bronchopulmonary dysplasia ( BPD ) , death discharge , pneumothorax , pneumomediastinum , pneumopericardium , pulmonary hemorrhage , patent ductus arteriosis ( PDA ) , intraventricular hemorrhage ( IVH ) , periventricular leukomalacia ( PVL ) , necrotizing enterocolitis ( NEC ) , retinopathy prematurity ( ROP ) , growth ( weight day 28 36 week PMA , and/or discharge ) , length hospital stay . Adverse event ( AEs ) serious adverse event ( SAEs ) monitor , collect , analyze , report . Safety monitor throughout study base prospectively defined complication ( safety outcomes ) allow report yet unidentified potential complication . All AEs SAEs report , SAEs report expedited basis per regulatory requirement timeframes responsible investigational review board ( IRBs ) , Data Safety Monitoring Board ( DSMB ) . Interim analysis perform independent statistician 50 patient enrol data submit DSMB member . They monitor adverse event , specifically , mortality make recommendation continuation study . The DSMB disclose finding avoid bias except issue continue discontinue statement . If statistically significant difference primary endpoint- need mechanical ventilation via endotracheal tube 7 day age ( p &lt; 0.02 ) statistically high incidence mortality within one treatment group , trial close midpoint result disclose . Statistical Methods Sample Size : A sample size 100 patient need . The need mechanical ventilation via endotracheal tube 7 day age preterm population report range 63 % ( Verder 1999 ) 43 % ( Dani 2004 ) . On basis data collect center publish data VLBW infant , sample size 50 infant group need demonstrate 50 % reduction need mechanical ventilation via endotracheal tube 7 day age ( power 0.8 α-error 0.05 ) . An additional 10 patient ( 10 % ) allow accommodate dropout . Primary Endpoint : Analyses primary endpoint base intention treat ( ITT ) analysis randomize , eligible subject . Statistical analysis perform use Student 's test continuous normally distribute variable Wilcoxon rank sum test non-parametric variable . Comparison proportion analysis categorical variable perform use 2-tailed Fisher 's exact test logistic regression analysis . A p value &lt; 0.05 consider statistically significant . Secondary Endpoints : The secondary efficacy analysis perform use ITT population . The following secondary variable analyze include need additional dos surfactant , duration mechanical ventilation supplemental oxygen , day nasal CPAP , postnatal steroid use BPD , growth ( weight day 28 36 week PMA , and/or discharge ) length hospital stay . A p-value le 0.05 consider significant test effect factor . A multiple regression analysis may employ require confounding effect identify within study ( e.g. , gestational age , race , center , antenatal postnatal steroid use ) .</detailed_description>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<criteria>1 . Estimated gestational age 26 29 + 6 week inclusive ; 2 . Inborn ; 3 . Birth Weight : ≥ 600 gram ; 4 . Required endotracheal intubation respiratory distress ; 5 . Has receive one dose poractant alfa 200mg/kg within 60 minute birth ; 6 . No known lethal congenital anomaly genetic syndrome ; 7 . No known lung maturity ; 8 . Signed parental inform consent 1 . Gestational age &lt; 26 week ≥ 30 week ; 2 . Birth weight less 600 gram ; 3 . Apgar score 0 one minute age ; 4 . Lethal congenital anomaly genetic syndrome identify antenatally within 60 minute birth</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Minutes</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>RDS</keyword>
	<keyword>Preterm</keyword>
	<keyword>SIMV</keyword>
	<keyword>NIPPV</keyword>
</DOC>